Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and MK0431A vs Pioglitazone in Type 2 Diabetes
NCT00541450Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change in Hemoglobin A1c at 40 weeks. Started Jan 2008; status: completed.
02
Drugs
sitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00541450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541450.